McKesson stock raises fiscal 2027 adjusted EPS guidance

McKesson reported fiscal 2027 second-quarter results on Wednesday, November 4, with revenue growth and higher adjusted profit prompting an increase in its full-year outlook. The healthcare services company said consolidated revenue reached USD 111.0 billion for the quarter ended September 30, 2026, up 8 percent from a year earlier.

In the same release, McKesson reported diluted earnings per share of USD 10.44, compared with USD 8.92 in the prior-year quarter. Adjusted earnings per diluted share, a non-GAAP measure, rose 18 percent to USD 11.68 from USD 9.86.

Profit growth broadens across segments

McKesson attributed the revenue increase mainly to higher prescription volumes in North American Pharmaceutical and continued demand in Oncology and Multispecialty. Prescription Technology Solutions also contributed to operating profit growth, while lower contributions from branded pharmaceuticals partly offset the gains.

Gross profit increased 10 percent to USD 3.9 billion, and operating profit rose 13 percent to USD 1.9 billion. Operating expenses increased 8 percent to USD 2.1 billion, but expenses as a percentage of gross profit improved by approximately 141 basis points year over year. The company said diluted weighted-average shares fell 6 percent to 116.7 million, reflecting continued share repurchases.

Higher guidance raises the bar

McKesson lifted its fiscal 2027 adjusted earnings-per-share guidance to USD 45.60 to USD 46.40 from the previous range of USD 44.20 to USD 45.00. The new range implies adjusted EPS growth of 17 percent to 19 percent versus the prior year. Chief Financial Officer Kenny Cheung said the increase reflected business strength and confidence in consistent execution.

Cash generation also strengthened during the quarter. Operating cash flow reached USD 3.1 billion and free cash flow amounted to USD 2.9 billion. For investors, the combination of volume-led distribution growth, operating leverage and the higher profit outlook supports the earnings case, although the branded-pharmaceutical environment remains a factor to monitor.

Real-time quote of McKesson stock: McKesson stock traded at 965.10 euros on Lang & Schwarz at 14:32 CET on Thursday, November 5, 2026.

The broader US market context is available in current market reports.

McKesson is scheduled to appear at the Jefferies Global Healthcare Conference on November 17, 2026. More news and analyses on McKesson stock will track the next signals on demand, margins and capital allocation.